Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

human MLC20 S19A (#RDB14160)

Shuttle vector to generate recombinant adenovirus expressing human MYL12B (mutant, S19A).

Clone info. Shuttle vector to generate recombinant adenovirus expressing human MYL12B (mutant, S19A).
Comment Expression was confirmed by the depositor with immunoblot and microphotographs.
Vector backbone pAxCAwtit (Cosmid, use packaging extracts for transforming E. coli host)
Size of vector backbone 45 kb
Selectable markers Amp^r
Gene/insert name Human MYL12B cDNA
Depositor|Developer Hirano, Katsuya |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] For for-profit-research purpose, please contact us. 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Hirano, M. et al., Sci. Rep. 6:20989, 2016)
Additional terms and conditions:
Regarding resources containing CAG promoter: In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation for the CAG promoter (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991) and an acknowledgment to Dr. Jun-ich Miyazaki of the Osaka University are requested.
Remarks Remember that you will be working with samples containing infectious virus.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。営利目的利用についてはお問い合わせください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Hirano, M. et al., Sci. Rep. 6:20989, 2016)。
MTAに書く付加的使用条件：
CAGプロモータを含むリソースについて: 利用者は、研究成果の公表にあたってCAGプロモータの文献 (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991)を引用し、大阪大学 宮崎純一博士への謝辞の表明を必要とする。
備考 このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB14160 human MLC20 S19A DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The human MLC20 S19A was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB14160).

Reference section:

Hirano, M., Hirano, K., Myosin di-phosphorylation and peripheral actin bundle formation as initial events during endothelial barrier disruption. Sci. Rep. 6: 20989 (2016). PMID 26863988. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB14160_A6Epp1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: pAxCA_R1
Sequence file: RDB14160_A6Epa.seq check
>D03455A3_A6Ep_pAxCA_F1_C12_09.ab1
    1 CCCTTTTCTT TCTTTTTCCT ACAGCTCCTG GGCAACGTGC TGGTTATTGT GCTGTCTCAT
   61 CATTTTGGCA AAGAATTGAT TTATCGATTT CGCGGGCCCC CATGTCGAGC AAAAAGGCAA
  121 AGACCAAGAC CACCAAGAAG CGCCCTCAGC GTGCAACAGC CAATGTGTTT GCCATGTTTG
  181 ACCAGTCACA GATTCAGGAG TTCAAAGAGG CCTTCAACAT GATTGATCAG AACAGAGATG
  241 GCTTCATCGA CAAGGAAGAT TTGCATGATA TGCTTGCTTC TCTAGGGAAG AATCCCACTG
  301 ATGCATACCT TGATGCCATG ATGAATGAGG CCCCAGGGCC CATCAATTTC ACCATGTTCC
  361 TGACCATGTT TGGTGAGAAG TTAAATGGCA CAGATCCTGA AGATGTCATC AGAAACGCCT
  421 TTGCTTGCTT TGATGAAGAA GCAACAGGCA CCATTCAGGA AGATTACCTA AGAGAGCTGC
  481 TGACAACCAT GGGGGATCGG TTTACAGATG AGGAAGTGGA TGAGCTGTAC AGAGAAGCAC
  541 CTATTGACAA AAAGGGGAAT TTCAATTACA TCGAGTTCAC ACGCATCCTG AAACATGGAG
  601 CCAAAGACAA AGATGACTGA AAGAACTTTA GCTAAAAGGG ATCAAATTAA TTAAACTAGT
  661 CTAGAATCGA TAATCAATTC ACTCCTCAGG TGCAGGCTGC CTATCAGAAG GTGGTGGCTG
  721 GTGTGGCCAA TGCCCTGGCT CACAAATACC ACTGAGATCT TTTTCCCCTC TGCCAAAAAT
  781 TATGGGGACA TCATGGAAAG CCCCCTTAAC ATCTCTGACA TTCTCTGCTC TAAATAAAAG
  841 AAAATTTTTA TTTTCTCATT TCGCAATAGT GTGTTTGAGA ATTTTTTTTG TGTCTTCTCA
  901 CTCGGAAAGA CATATGGGGA GGGCAAATTC ATTTAAAACA TCAGATGATA TTGTTTAGAG
  961 TTTGGCACAT ATGCCCATAT GCTGGCTGCC ACATATGCTG CTTGCCAATG AAACAAAGGT
 1021 TTGGCTATAA AGAGAAGGTT CCAATCAGTA ATTATGGAAA CCAGCCCCCC TGCCTTGTCA
1081 TCCGTTACTC GATAGGAATA GTTGATAGTC TAGAATTTTT TTAATAGTG
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Hirano, M., Myosin di-phosphorylation and peripheral actin bundle formation as initial events during endothelial barrier disruption. Sci. Rep. 6: 20989 (2016). PMID 26863988. [link to RRC of NBRP]